Private Companies 26
August 16, 2017: Becton Dickinson Pty. Ltd. issued new European patent [EP3205270 (A1)]
NEWS BITES - PRIVATE COMPANIES
Becton Dickinson Pty. Ltd. has been issued a new European patent titled "WEARABLE ELECTRONIC DEVICE FOR ENHANCING VISUALIZATION DURING INSERTION OF AN INVASIVE DEVICE" by the European Patent Office.
A system for vein access confirmation, comprising: a wearable electronic device configured to be worn by a user comprising: a housing; one or more imaging sensors associated with the housing; a data reporting accessory for providing data to the user; and at least one microprocessor for managing and processing images from the one or more imaging sensors; an external sub-dermal imaging device for acquiring images of sub-dermal structures positioned adjacent to a proposed vascular access site; and a vascular access device for insertion into a vein of a patient at the vascular access site, wherein the wearable electronic device is configured to process images obtained by the sub-dermal imaging device to determine a preferred vein for insertion of the vascular access device, to estimate a preferred size for an injection portion of the vascular access device based on the size of the preferred vein, and to report the preferred size for the injection portion to the user via the data reporting accessory.
Source: European Patent Office
SECTION 1 BECTON DICKINSON PTY. LTD. PROFILE
SECTION 2 PRESS RELEASES: 2017
SECTION 3 OTHER NEWS: 2017
SECTION 4 BECTON DICKINSON PTY. LTD. PATENTS
SECTION 1 BECTON DICKINSON PTY. LTD. PROFILE
Becton Dickinson Pty. Ltd. offers medical devices, diagnostics, and bioscience solutions. The company's medical products include anesthesia systems, diabetes care products, IV accessories, IV cannulae and integrated systems, pharmaceutical systems, sharps disposal systems, and site preparation products. The companys diagnostic systems comprise prepared media products, blood culture products, collection and transport systems, dehydrated culture media and ingredients, direct testing/serology solutions, environmental systems, identification/susceptibility solutions, molecular diagnostics, stains and reagents, conventional and safety needles and syringes, sharps disposal systems, ophthalmic surgical instruments, critical care monitoring devices, and bandages and braces. It also offers pre-analytical systems, such as automated urinalysis solutions, blood collection solutions, and specimen collection solutions. In addition, the company provides bioscience tools to life scientists, clinical researchers, and clinicians. Becton Dickinson Pty. Ltd. was founded in 1981 and is headquartered in North Ryde, Australia. The company has additional offices in Auckland, Melbourne, Brisbane, Perth, and Adelaide. Becton Dickinson Pty. Ltd. operates as a subsidiary of Becton, Dickinson and Company.
Industry: Healthcare Equipment/Supplies
SECTION 2 PRESS RELEASES: 2017
April 23: BD Announces Appointment of Tom Polen as President
FRANKLIN LAKES, N.J., April 23, 2017 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as president of BD, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments - the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the C. R. Bard, Inc. (NYSE: BCR) businesses following the close of BD's acquisition of Bard, which was also announced today. Mr. Polen, currently executive vice president and president of the BD Medical Segment, will continue to report to Vince Forlenza, who remains chairman and CEO of BD.
"Tom brings a deep understanding of BD, the medical technology industry and the global healthcare environment," said Vince Forlenza, chairman and CEO of BD. "His well-deserved promotion reflects his leadership in developing and implementing BD Medical's strategy and vision, his proven track record of delivering strong performance, and his commitment to ensuring the ongoing success of BD and its associates. I look forward to continuing to work closely with the Board, Tom, our entire leadership team, and our associates to successfully integrate and grow the combined company in the years ahead, as we deliver on our purpose of advancing the world of health."
Mr. Polen said, "This is an exciting time for BD. I am honored to serve in this new role as we continue our transformation into a medical technology leader focused on delivering solutions that advance the discovery, diagnostics and delivery of health care globally and helping health care providers worldwide to improve both the process of care and the treatment of disease."
Mr. Polen originally joined BD in 1999. His BD career has spanned sales, marketing, general management and strategic planning roles.
April 23: BD to Acquire Bard for $24 Billion
Will Create Highly Differentiated Medical Technology Company Focused on Delivering Innovative Healthcare Solutions to Improve Clinical and Economic Outcomes Will Build on BD's Leadership Position in Medication Management and Infection Prevention; Will Increase Opportunities in Innovative Fast-Growing Clinical Areas Financially Compelling Transaction; Immediately Accretive and Expected to Generate High Single-Digit Accretion to Adjusted EPS in Fiscal Year 2019 Tom Polen Named BD President
FRANKLIN LAKES, NJ and MURRAY HILL, NJ (April 23, 2017) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.
The combination will create a highly differentiated medical technology company uniquely positioned to improve both the process of care and the treatment of disease for patients and healthcare providers. The transaction will build on BD's leadership position in medication management and infection prevention with an expanded offering of solutions across the care continuum. Additionally, Bard's strong product portfolio and innovation pipeline will increase BD's opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined company in non-U.S. markets.
This financially compelling transaction will be immediately accretive and is expected to generate high-single digit accretion to adjusted earnings per share (EPS) in fiscal year 2019.
February 21: BD Partnership Honored by U.S. Chamber of Commerce Foundation at the Health Means Business National Summit with Healthy10 Award
WASHINGTON, Feb. 21, 2017 - A partnership among BD (Becton Dickinson and Company) (NYSE: BDX), Direct Relief and the National Association of Community Health Centers was selected as one of three winners for the Healthy10 Healthy Community award. The BD Helping Build Healthy Communities(TradeMark) partnership was honored at the first national summit and Healthy10 Awards in Washington D.C. on Feb. 16.
The Health Means Business campaign is a partnership of the U.S. Chamber of Commerce Foundation and the Robert Wood Johnson Foundation, which encourages businesses to invest in the health of local communities. The Healthy10 Awards ceremony honors 10 specific partnerships and initiatives that are dedicated to improving the health of communities across the United States.
This award highlights the BD Helping Build Healthy Communities partnership, a multi-year initiative that expands access and improves care for underserved and vulnerable populations throughout the United States.
"The BD Helping Build Healthy Communities partnership increases access to care to communities severely in need," said Marc DeCourcey, senior vice president of the U.S. Chamber of Commerce Foundation. "It's an honor to recognize BD, Direct Relief and the National Association of Community Health Centers for their outstanding partnership."
The initiative, funded by $5 million in cash and product donations from BD, is implemented together with Direct Relief and the National Association of Community Health Centers. The program provides award funding and products to community health centers to support innovative approaches in the delivery of health care to underserved populations related to the prevention and treatment of diabetes, cervical cancer and HIV.
"BD's Helping Build Healthy Communities program is a perfect example of the type of partnership that can make a tremendous difference in improving the health of people who have limited access to the health services that everyone needs," said Thomas Tighe, president and CEO of Direct Relief.
February 17: Events Calendar: BD to Present at Investor Healthcare Conferences
Franklin Lakes, NJ (February 17, 2017) - BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences.
2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 2:05 p.m. ET
Barclays Global 2017 Healthcare Conference
March 14, 2017
10:45 a.m. ET
Live webcasts of BD's presentations can be accessed on the BD corporate website at www.bd.com/investors. They will be available for replay for a period of seven days after each conference.
SECTION 3 OTHER NEWS: 2017
August 14: BD Expands Suite of Blood Culture Offerings with New BD BACTEC(TradeMark) Standard Aerobic & Standard Anaerobic Plastic Bottles
FRANKLIN LAKES, N.J., August 14, 2017 - BD (Becton, Dickinson and Company), a leading global medical technology company, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD BACTEC(TradeMark) Standard Aerobic and Standard Anaerobic blood culture bottles in plastic. This marks further expansion of the blood culture bottles available in plastic across BD's industry-leading BD BACTEC(TradeMark) platform.
The new BD BACTEC(TradeMark) Standard Aerobic and Standard Anaerobic plastic blood culture bottles are designed for customer convenience for the qualitative culture and recovery of aerobic organisms (bacteria & yeast) and anaerobic microorganisms, respectively, from adult blood culture specimens. This latest addition to BD's full spectrum of sepsis and health care associated infection solutions represents BD's continued commitment to meeting customer needs and enhancing laboratory efficiencies. The BD BACTEC(TradeMark) plastic bottle offerings are smaller and lighter, allowing for easy and safe handling during collection, transport and disposal.
"We are very pleased to announce the expansion of our BD BACTEC(TradeMark) blood culture plastic bottle offering," said Steve Conly, Vice President of Microbiology Diagnostics Systems for BD Life Sciences.
SECTION 4 BECTON DICKINSON PTY. LTD. PATENTS
PREVIOUS 10 PATENT STORIES:
August 9, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3202454 (A1)]
The present invention extends to a blood control catheter valve for use in a catheter adapter. The blood control catheter value employs an actuator for bypassing a septum to open the blood control catheter valve. The actuator includes flexible retention arms positioned on one end which retract into the body of the actuator while the end of the actuator passes through the septum, and then expand outwardly to maintain the actuator positioned within the septum. This design facilitates the manufacturing of catheter adapters (as well as blood control catheter valves and other components that attach to the catheter adapter) because the design can reduce the tolerance requirements of such components. Further, the design provides a reliable blood control catheter valve that does not require the catheter adapter to be increased in size to accommodate the valve
July 19, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3192545 (A1)]
An apparatus is disclosed for storing and changing needles for a medicament delivery device having a medicament container, including a fixed mount for connecting the apparatus with the medicament delivery device, a needle holder displaceable along a circuitous path and connecting a plurality of needles displaceably disposed thereon, and a guide member for guiding displacement of the needle holder, the guide member being disposed about the fixed mount. The apparatus also includes a user interface rotatably disposed about the fixed mount and having at least one internal engaging structure for displacing the needle holder along the circuitous path
June 28, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3184133 (A1)]
An infusion set has an integrated ballistic inserter that can insert a needle at a controlled high rate of speed to a depth to deliver content to the upper 3 mm of skin surface, and a skin securing, adhesive layer to secure the skin surface at the insertion site such that the inserter that can insert a needle without a risk of tenting of the skin surface. A driving spring of the ballistic inserter is captured within the ballistic inserter, and can be released by user operation, to insert a needle at such a controlled rate of speed
May 31, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3173122 (A1)]
Drug delivery devices having integrated non-luer connectors are described. An exemplary drug delivery device includes a container with a non-luer connector that prevents connection of a standard female luer connector to the container. One or more embodiments pertain to a container with a non-luer connector that prevents the formation of a fluid-tight seal between a standard female luer connector and the container. A non-luer connector for attachment to a container having a non-luer element is also described
April 26, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3159697 (A1)]
Systems and methods for performing simultaneous nucleic acid amplification and detection. The systems and methods comprise methods for managing a plurality of protocols in conjunction with directing a sensor array across each of a plurality of reaction chambers. In certain embodiments, the protocols comprise thermocycling profiles and the methods may introduce offsets and duration extensions into the thermocycling profiles to achieve more efficient detection behaviour
April 26, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3159031 (A1)]
A septum (114) to control blood flow through an intravenous catheter in accordance with the present invention may include a substantially resilient helical outer shell (116) and an inner valve portion (118) formed therein. The inner valve portion may be configured to open upon compressing the substantially resilient helical outer shell. In some embodiments, the inner valve portion may include mating portions that substantially align to provide fluid leakage therebetween. Compressing the substantially resilient helical outer shell by, for example, inserting a Luer device into a catheter adapter containing the substantially resilient outer shell, may cause the mating portions to misalign, thereby creating a fluid path
April 24, 2017 Becton Dickinson Pty. Ltd. issued new European patent [ES2609774 (T3)]
An apparatus is disclosed for storing and changing needles for connection with a medicament delivery device, comprising an inner housing, a reservoir disposed within the inner housing, and a needle holder disposed within the inner housing, for fluidly connecting a medicament container of the medicament delivery device with the reservoir. The apparatus also includes a plurality of patient needles displaceably disposed on the needle holder, and an outer housing displaceably disposed about the inner housing and providing a user interface to individually select one of the plurality of patient needles, connect the selected needle with the reservoir, expose the selected needle outside of the apparatus for injection, and store the selected needle
April 24, 2017 Becton Dickinson Pty. Ltd. issued new European patent [ES2609768 (T3)]
An apparatus to control blood flow through an intravenous catheter in accordance with the present invention may include a substantially resilient helical outer shell and an inner valve portion formed therein. The inner valve portion may be configured to open upon compressing the substantially resilient helical outer shell. In some embodiments, the inner valve portion may include mating portions that substantially align to provide fluid leakage therebetween. Compressing the substantially resilient helical outer shell by, for example, inserting a Luer device into a catheter adapter containing the substantially resilient outer shell, may cause the mating portions to misalign, thereby creating a fluid path
April 19, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3156704 (A1)]
A system for controlling fluid flow in a catheter assembly, comprising: an intravenous catheter assembly having a catheter adapter (14) comprising an inner lumen; an integrated septum (50) and septum actuator (80) disposed within a portion of the inner lumen, the integrated septum and septum actuator comprises a base having a fluid pathway and an extension arm extending outwardly from the base, the extension arm being coupled to a septum being deformable from a relaxed position to a stressed position, wherein a pathway around an outer surface of the septum is closed when the septum is in the relaxed position, and the pathway around the outer surface of the septum is open when the septum is in the stressed position
April 19, 2017 Becton Dickinson Pty. Ltd. issued new European patent [EP3156095 (A1)]
A peripheral catheter (100) having a catheter tip diffuser (320) for reducing an exit velocity of an infusant within the catheter. Pluralities of diffusion side holes are provided on the tip portion of the catheter. Some examples further include pluralities of annularly arranged, staggered diffusion holes provided on the tip portion of an intravenous catheter to streamline infusant issued from the diffusion holes. An inner surface of each diffusion hole is further angled relative to the inner surface of the catheter lumen such that an infusant within the lumen exits the catheter though the diffusion holes at an angle less than 90''
Created by www.buysellsignals.com for News Bites Finance